• Je něco špatně v tomto záznamu ?

Observed benefit and safety of aflibercept in elderly patients with metastatic colorectal cancer: An age-based analysis from the randomized placebo-controlled phase III VELOUR trial

P. Ruff, E. Van Cutsem, R. Lakomy, J. Prausova, GA. van Hazel, VM. Moiseyenko, K. Soussan-Lazard, E. Dochy, E. Magherini, T. Macarulla, D. Papamichael,

. 2018 ; 9 (1) : 32-39. [pub] 20170812

Jazyk angličtina Země Nizozemsko

Typ dokumentu klinické zkoušky, fáze III, časopisecké články, multicentrická studie, randomizované kontrolované studie, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc19028764

OBJECTIVES: Aflibercept (ziv-aflibercept) significantly improves progression-free (PFS) and overall survival (OS) when added to 5-fluorouracil, leucovorin and irinotecan (FOLFIRI), compared with FOLFIRI alone, in patients with metastatic colorectal cancer previously treated with oxaliplatin-based therapy. This subset analysis of the VELOUR study investigates aflibercept plus FOLFIRI versus placebo plus FOLFIRI according to age. METHODS: Efficacy and safety were analyzed by treatment arm and age (≥ or <65years). RESULTS: Overall, 443 patients were ≥65years old (205 in aflibercept arm; 238 in placebo arm) and 783 were <65years old (407 in aflibercept arm; 376 in placebo arm). Median OS was 12.6 versus 11.3months (hazard ratio [HR]: 0.85; 95.34% CI 0.68-1.07) in patients ≥65years old and 14.5 versus 12.5months (HR: 0.80; 95.34% CI 0.67-0.95) in those patients <65years old, for patients receiving FOLFIRI plus aflibercept or placebo, respectively. There was no interaction between treatment and age. Treatment-emergent adverse events (AEs) were comparable for patients <65years and ≥65years old. The incidence of grade 3/4 AEs was higher for patients ≥65years old than for those <65years old in both the aflibercept (89.3% versus 80.5%) and placebo (67.4% versus 59.4%) arms. Interaction tests for grade 3/4 antiangiogenic agent-related AEs suggested no heterogeneity between the older and younger patient populations (p>0.1). CONCLUSION: A limited but consistent benefit on both OS and PFS was associated with the addition of aflibercept to FOLFIRI compared with placebo in patients <65 and ≥65years old, with a marked but manageable increase in the toxicity profile in older patients. TRIAL REGISTRATION: clinicaltrials.govNCT00561470.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19028764
003      
CZ-PrNML
005      
20190916134311.0
007      
ta
008      
190813s2018 ne f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.jgo.2017.07.010 $2 doi
035    __
$a (PubMed)28807738
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ne
100    1_
$a Ruff, Paul $u University of Witwatersrand Faculty of Health Sciences, Johannesburg, South Africa. Electronic address: pruff@iafrica.com.
245    10
$a Observed benefit and safety of aflibercept in elderly patients with metastatic colorectal cancer: An age-based analysis from the randomized placebo-controlled phase III VELOUR trial / $c P. Ruff, E. Van Cutsem, R. Lakomy, J. Prausova, GA. van Hazel, VM. Moiseyenko, K. Soussan-Lazard, E. Dochy, E. Magherini, T. Macarulla, D. Papamichael,
520    9_
$a OBJECTIVES: Aflibercept (ziv-aflibercept) significantly improves progression-free (PFS) and overall survival (OS) when added to 5-fluorouracil, leucovorin and irinotecan (FOLFIRI), compared with FOLFIRI alone, in patients with metastatic colorectal cancer previously treated with oxaliplatin-based therapy. This subset analysis of the VELOUR study investigates aflibercept plus FOLFIRI versus placebo plus FOLFIRI according to age. METHODS: Efficacy and safety were analyzed by treatment arm and age (≥ or <65years). RESULTS: Overall, 443 patients were ≥65years old (205 in aflibercept arm; 238 in placebo arm) and 783 were <65years old (407 in aflibercept arm; 376 in placebo arm). Median OS was 12.6 versus 11.3months (hazard ratio [HR]: 0.85; 95.34% CI 0.68-1.07) in patients ≥65years old and 14.5 versus 12.5months (HR: 0.80; 95.34% CI 0.67-0.95) in those patients <65years old, for patients receiving FOLFIRI plus aflibercept or placebo, respectively. There was no interaction between treatment and age. Treatment-emergent adverse events (AEs) were comparable for patients <65years and ≥65years old. The incidence of grade 3/4 AEs was higher for patients ≥65years old than for those <65years old in both the aflibercept (89.3% versus 80.5%) and placebo (67.4% versus 59.4%) arms. Interaction tests for grade 3/4 antiangiogenic agent-related AEs suggested no heterogeneity between the older and younger patient populations (p>0.1). CONCLUSION: A limited but consistent benefit on both OS and PFS was associated with the addition of aflibercept to FOLFIRI compared with placebo in patients <65 and ≥65years old, with a marked but manageable increase in the toxicity profile in older patients. TRIAL REGISTRATION: clinicaltrials.govNCT00561470.
650    _2
$a adenokarcinom $x farmakoterapie $7 D000230
650    _2
$a věkové faktory $7 D000367
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a inhibitory angiogeneze $x aplikace a dávkování $x škodlivé účinky $7 D020533
650    _2
$a protokoly protinádorové kombinované chemoterapie $x aplikace a dávkování $x škodlivé účinky $7 D000971
650    _2
$a kamptothecin $x aplikace a dávkování $x škodlivé účinky $x analogy a deriváty $7 D002166
650    _2
$a kolorektální nádory $x farmakoterapie $7 D015179
650    _2
$a přežití bez známek nemoci $7 D018572
650    _2
$a dvojitá slepá metoda $7 D004311
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a fluoruracil $x aplikace a dávkování $x škodlivé účinky $7 D005472
650    _2
$a lidé $7 D006801
650    _2
$a Kaplanův-Meierův odhad $7 D053208
650    _2
$a leukovorin $x aplikace a dávkování $x škodlivé účinky $7 D002955
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a metastázy nádorů $7 D009362
650    _2
$a receptory vaskulárního endoteliálního růstového faktoru $x aplikace a dávkování $7 D040262
650    _2
$a rekombinantní fúzní proteiny $x aplikace a dávkování $x škodlivé účinky $7 D011993
655    _2
$a klinické zkoušky, fáze III $7 D017428
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a randomizované kontrolované studie $7 D016449
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Van Cutsem, Eric $u University Hospitals Leuven and KU Leuven, Belgium.
700    1_
$a Lakomy, Radek $u Masaryk Memorial Cancer Institute, Brno, Czech Republic.
700    1_
$a Prausova, Jana $u University Hospital Motol, Prague, Czech Republic.
700    1_
$a van Hazel, Guy A $u University of Western Australia, Western Australia, Australia.
700    1_
$a Moiseyenko, Vladimir M $u Cancer Center, St-Petersburg, Russian Federation.
700    1_
$a Soussan-Lazard, Karen $u Sanofi, Vitry-sur-Seine, France.
700    1_
$a Dochy, Emmanuelle $u Sanofi, Diegem, Belgium.
700    1_
$a Magherini, Emmanuelle $u Sanofi, Vitry-sur-Seine, France.
700    1_
$a Macarulla, Teresa $u Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Barcelona, Spain.
700    1_
$a Papamichael, Demetris $u Bank of Cyprus Oncology Centre, Nicosia, Cyprus.
773    0_
$w MED00200165 $t Journal of geriatric oncology $x 1879-4076 $g Roč. 9, č. 1 (2018), s. 32-39
856    41
$u https://pubmed.ncbi.nlm.nih.gov/28807738 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20190813 $b ABA008
991    __
$a 20190916134658 $b ABA008
999    __
$a ok $b bmc $g 1433913 $s 1067224
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2018 $b 9 $c 1 $d 32-39 $e 20170812 $i 1879-4076 $m Journal of geriatric oncology $n J Geriatr Oncol $x MED00200165
LZP    __
$a Pubmed-20190813
Zpět

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace